254 related articles for article (PubMed ID: 15475985)
21. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
[TBL] [Abstract][Full Text] [Related]
23. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
Dyet K; Devoy A; McDowell R; Martin D
Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
[TBL] [Abstract][Full Text] [Related]
25. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
[TBL] [Abstract][Full Text] [Related]
26. Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand.
Sexton K; Lennon D; Oster P; Aaberge I; Martin D; Reid S; Wong S; O'Hallahan J
N Z Med J; 2004 Aug; 117(1200):1 p preceding U1027. PubMed ID: 15481128
[TBL] [Abstract][Full Text] [Related]
27. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
28. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
[TBL] [Abstract][Full Text] [Related]
29. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
Lennon D
Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
[No Abstract] [Full Text] [Related]
30. The challenge of post-implementation surveillance for novel meningococcal vaccines.
Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
[TBL] [Abstract][Full Text] [Related]
31. Recent developments in vaccines to prevent meningococcal serogroup B infections.
Vermont CL; van den Dobbelsteen GP; de Groot R
Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of vaccine breakthrough cases following MeNZB vaccination.
McNicholas A; Galloway Y; Martin D; Sexton K; O'Hallahan J
N Z Med J; 2008 Apr; 121(1272):38-46. PubMed ID: 18425153
[TBL] [Abstract][Full Text] [Related]
34. Mum's the word: factors that influenced young adults' participation in the New Zealand Meningococcal B immunisation programme.
Bland M; Clear GM; Grogan A; Hoare K; Waldock J
N Z Med J; 2009 Dec; 122(1307):30-8. PubMed ID: 20148042
[TBL] [Abstract][Full Text] [Related]
35. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
Lennon D
Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
[No Abstract] [Full Text] [Related]
36. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
McNicholas A; Galloway Y; Stehr-Green P; Reid S; Radke S; Sexton K; Kieft C; Macdonald C; Neutze J; Drake R; Isaac D; O'Donnell M; Tatley M; Oster P; O'Hallahan J
Hum Vaccin; 2007; 3(5):196-204. PubMed ID: 17660718
[TBL] [Abstract][Full Text] [Related]
37. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
[TBL] [Abstract][Full Text] [Related]
38. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
[No Abstract] [Full Text] [Related]
39. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
40. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario.
Khalil MK; Borrow R
Travel Med Infect Dis; 2009 Jul; 7(4):231-4. PubMed ID: 19717106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
